DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ticar (Ticarcillin Disodium) - Summary



brand of
sterile ticarcillin disodium
for Intramuscular or Intravenous Administration

Ticar is a semisynthetic injectable penicillin derived from the penicillin nucleus, 6-aminopenicillanic acid.

Ticar is indicated for the treatment of the following infections:

Bacterial septicemia

Skin and soft-tissue infections

Acute and chronic respiratory tract infections‡§

Caused by susceptible strains of Pseudomonas aeruginosa, Proteus species (both indole-positive and indole-negative) and Escherichia coli.

§ Though clinical improvement has been shown, bacteriological cures cannot be expected in patients with chronic respiratory disease or cystic fibrosis.

Genitourinary tract infections (complicated and uncomplicated) due to susceptible strains of Pseudomonas aeruginosa, Proteus species (both indole-positive and indole-negative), Escherichia coli, Enterobacter and Streptococcus faecalis (enterococcus).

Ticarcillin is also indicated in the treatment of the following infections due to susceptible anaerobic bacteria:

  1. Bacterial septicemia.
  2. Lower respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess.
  3. Intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract).
  4. Infections of the female pelvis and genital tract, such as endometritis, pelvic inflammatory disease, pelvic abscess and salpingitis.
  5. Skin and soft-tissue infections.

Although ticarcillin is primarily indicated in gram-negative infections, its in vitro activity against gram-positive organisms should be considered in treating infections caused by both gram-negative and gram-positive organisms (see Microbiology).

Based on the in vitro synergism between ticarcillin and gentamicin sulfate, tobramycin sulfate or amikacin sulfate against certain strains of Pseudomonas aeruginosa, combined therapy has been successful, using full therapeutic dosages. (For additional prescribing information, see the gentamicin sulfate, tobramycin sulfate and amikacin sulfate package inserts.)

NOTE: Culturing and susceptibility testing should be performed initially and during treatment to monitor the effectiveness of therapy and the susceptibility of the bacteria.

See all Ticar indications & dosage >>


Media Articles Related to Ticar (Ticarcillin)

Hives (Urticaria & Angioedema)
Source: MedicineNet Microsporidiosis Specialty [2016.11.14]
Title: Hives (Urticaria & Angioedema)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/14/2016 12:00:00 AM

more news >>

Published Studies Related to Ticar (Ticarcillin)

Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. [2007.09]
BACKGROUND: Ertapenem, a group I carbapenem antibiotic, has been shown to be safe and effective in treating adults with complicated intra-abdominal (cIAI) or acute pelvic infection (API). This study evaluated ertapenem for treating these infections in children... CONCLUSIONS: This study suggests that ertapenem is generally safe and efficacious for treating cIAI or API in pediatric patients.

A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients. [2011]
tolerability profile of both drugs... CONCLUSION: CEFEPIME regimen was more effective than TC regimen, with a

High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. [2010.07]
BACKGROUND: The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin-clavulanate 400mg/kg/day divided every 6h, (maximum 24 g/day). This dosing strategy is higher than the Cystic Fibrosis Foundation (CFF) recommendations and the Food and Drug Administration (FDA) approved package labeling. The purpose is to determine the safety of this dosing regimen... CONCLUSIONS: Higher than FDA approved doses of ticarcillin-clavulanate may be safely used in the treatment of exacerbations in pediatric cystic fibrosis patients. Copyright 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. [2005.06]
Continuous infusion (CI) ticarcillin-clavulanate is a potential therapeutic improvement over conventional intermittent dosing because the major pharmacodynamic (PD) predictor of efficacy of beta-lactams is the time that free drug levels exceed the MIC... Home CI of ticarcillin-clavulanate is a safe, effective, convenient and practical therapy and is a therapeutic advance over traditional intermittent dosing when used in the home setting.

Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. [2005.03]
Three captive loggerhead sea turtles, Caretta caretta, were used in four trials, one i.v...

more studies >>

Clinical Trials Related to Ticar (Ticarcillin)

Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants [Withdrawn]
This study will evaluate the safety, tolerability and PK of ticarcillin-clavulanate in infants <91 days of age with suspected systemic infection.

Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio) [Completed]

A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections [Completed]
The purpose of this study is to compare the safety and effectiveness of levofloxacin (an antibiotic) with ticarcillin/clavulanate alone or followed by amoxicillin/clavulanate in the treatment of complicated skin infections.

Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) [Completed]

more trials >>

Page last updated: 2016-11-14

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017